Librexia Acs
Posted Date: Mar 5, 2025
- Investigator: Naseer Khan
- Specialties:
- Type of Study: Drug
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE). The rationale for this study is that FXIa inhibition has the potential to reduce thrombin generation thereby preventing vascular occlusion and embolism with minimal impairment of hemostasis in patients with atherosclerotic CAD, including those after an ACS event.
Criteria:
Null
Keywords:
Oral Milvexian Within 7 Days Of Acute Coronary Syndrome
For More Information:
Elias Shamieh
513-558-3016
shamiees@ucmail.uc.edu